Bocom Intl: Guangzhou launches first batch of innovative drugs and medical devices catalog, focusing on innovation and consumer properties as symbols.
Following the introduction of policies encouraging the innovation of pharmaceuticals, the latest innovative drug and medical device product catalog released by Guangzhou will further provide full-chain, all-field support to the high-quality development of the biomedical industry.
According to reports, Beigene (06160) Greater China Chief Commercial Officer Yin Min is being investigated by regulatory institutions for reasons unrelated to the company's own operation.
King's Finance News | Today, there are rumors in the market that beigene (06160) Chief Commercial Officer for Greater China, Yin Min, is being investigated by regulatory institutions. The journalist confirmed this news from authoritative sources. Informed sources claimed that Yin Min's investigation is unrelated to beigene's own operation. Influenced by this news, Hong Kong stocks plunged over 6% in the afternoon, while A-shares of beigene (688235) dropped more than 10% briefly, with subsequent declines quickly narrowing down.
Sector Update: Health Care Stocks Softer Late Afternoon
Indaptus Therapeutics Shares Rise After Pact to Develop Cancer Treatment
BeiGene Is Maintained at Overweight by JP Morgan
BeiGene Analyst Ratings
BeiGene (NASDAQ:BGNE) Shareholders Have Earned a 9.6% CAGR Over the Last Five Years
Indaptus Therapeutics Announces Clinical Supply Agreement With BeiGene To Evaluate Novel Cancer Treatment Combinations
Express News | Indaptus Therapeutics Announces Clinical Supply Agreement With Beigene to Evaluate Novel Cancer Treatment Combinations
J.P. Morgan Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $235
Hong Kong stock innovative drugs sector once again welcomes national market sentiment, with "real innovation" becoming a key layout.
For domestic innovative drug enterprises, the medical insurance catalog has now become a 'threshold'. As long as the innovative drug enterprises successfully cross the threshold, they can rely on the logic of trading price for quantity to achieve rapid volume expansion of products, thereby crossing a major step in the company's cash realization speed and hematopoietic ability.
Express News | Beigene Ltd : JP Morgan Raises Target Price to $235 From $200
TD Cowen Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $254
BeiGene Canada Proud National Sponsor of the Leukemia & Lymphoma Society of Canada's 2024 Light The Night
TD Cowen Keeps Their Buy Rating on BeiGene (BGNE)
Express News | The Committee For Medicinal Products For Human Use Of The European Medicines Agency Issued Positive Opinions Recommending An Extended Authorization For BeiGene's Tevimbra (Tislelizumab) In Gastric Or Gastroesophageal Junction Adenocarcinoma And...
BeiGene Receives Positive CHMP Opinions for TEVIMBRA as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
Express News | Beigene Receives Positive Chmp Opinions for Tevimbra® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
Nomura Adjusts BeiGene's Price Target to HK$174.91 From HK$158.37, Keeps at Buy
Zhaojin International: China Meheco Group's industry is expected to "outperform the market" Focus on the health insurance opportunities of innovative varieties.
CICC released research reports stating that benefited from overseas interest rate cuts and domestic macroeconomic improvement, the pharmaceutical industry, as a high elasticity sector, is expected to outperform the broader market. The firm is bullish on CXO, innovative drugs, consumer healthcare, and medical equipment sectors; bullish on Wuxi Apptec (02359), BeiGene (06160), Innovent Bio (01801), Kendallo Bio (06990), Juji Biotech (02367), 3SBio (01530), Shenzhen Mindray Bio-medical Electronics (300760.SZ). The report stated that the MSCI China Healthcare Index has cumulatively declined by 14.1% year-to-date, underperforming the MSCI China Index.